Real-world effectiveness and safety of nemolizumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study

Eur J Dermatol. 2023 Dec 1;33(6):691-692. doi: 10.1684/ejd.2023.4551.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Dermatitis, Atopic* / drug therapy
  • Humans
  • Japan
  • Pruritus
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • nemolizumab
  • Antibodies, Monoclonal, Humanized